Recursion Pharmaceuticals, Inc. (RXRX) Key Metrics
RXRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.86B
- Enterprise value
- $1.52B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 33.9 10-yr median 34.1
- Price / book
- 2.2 10-yr median 2.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.03
RXRX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRXRX valuation Price multiples at each fiscal year-end price.
RXRX returns How much profit the business earns on the capital it uses.
RXRX per-share figures Results divided by the shares outstanding at year-end.
RXRX financial health Debt, liquidity and how easily interest is covered.
RXRX efficiency & capital use Working capital cycle and where the cash goes.
RXRX valuation history
RXRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RXRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RXRX price vs earnings per share
RXRX key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $1.83B | $1.85B | $2.05B | $1.35B | $2.92B | — | — |
| Enterprise value | $1.16B | $1.37B | $1.71B | $854.5M | $2.41B | — | — |
| Price / sales | 24.5 | 31.5 | 46.7 | 34.1 | 291.7 | — | — |
| Price / book | 1.6 | 1.8 | 4.4 | 2.8 | 5.4 | — | — |
| EV / sales | 15.6 | 23.2 | 38.9 | 21.5 | 241.2 | — | — |
| Earnings yield | −35.2% | −25.0% | −16.0% | −17.7% | −6.1% | — | — |
| Free cash flow yield | −20.7% | −20.1% | −14.7% | −8.9% | −6.8% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $4.09 | $6.76 | $9.86 | $7.71 | $17.13 | — | — |
| Per share | |||||||
| Revenue per share | $0.17 | $0.21 | $0.21 | $0.23 | $0.06 | $0.02 | $0.01 |
| Earnings per share | −$1.44 | −$1.69 | −$1.58 | −$1.36 | −$1.05 | −$0.52 | −$0.38 |
| Operating cash flow per share | −$0.83 | −$1.31 | −$1.38 | −$0.48 | −$0.93 | −$0.27 | −$0.34 |
| Free cash flow per share | −$0.85 | −$1.36 | −$1.44 | −$0.69 | −$1.17 | −$0.31 | −$0.37 |
| Cash per share | $1.66 | $2.17 | $1.88 | $3.13 | $3.03 | $1.58 | $0.42 |
| Book value per share | $2.53 | $3.77 | $2.23 | $2.77 | $3.19 | −$1.24 | −$0.75 |
| Tangible book value per share | $1.47 | $2.01 | $1.80 | $2.76 | $3.18 | −$1.26 | −$0.75 |
| Capex per share | $0.01 | $0.05 | $0.06 | $0.21 | $0.23 | $0.04 | $0.02 |
| Debt per share | $0.17 | $0.40 | $0.24 | $0.29 | $0.07 | $0.09 | $0.10 |
| Shares outstanding | 447.4M | 274.2M | 207.9M | 175.5M | 170.3M | 165.8M | 165.8M |
| Change in shares outstanding | +63.2% | +31.9% | +18.4% | +3.1% | +2.7% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −59.5% | −61.9% | −69.1% | −46.5% | −105.8% | — | — |
| Return on invested capital (ROIC) | −100.9% | −112.7% | −505.4% | — | — | — | — |
| Return on assets (ROA) | −44.1% | −44.1% | −48.4% | −36.5% | −39.2% | −43.5% | −61.6% |
| Return on tangible assets | −64.3% | −48.1% | −58.0% | −34.2% | −29.3% | −29.4% | −61.6% |
| Free cash flow margin | −506.5% | −633.7% | −684.5% | −304.6% | — | — | — |
| Financial health | |||||||
| Total debt | $78.0M | $108.5M | $50.7M | $51.0M | $11.5M | $15.7M | $16.2M |
| Cash & short-term investments | $743.3M | $594.4M | $391.6M | $549.9M | $516.6M | $262.1M | $69.9M |
| Net debt | −$665.3M | −$485.9M | −$340.9M | −$498.9M | −$505.1M | −$246.5M | −$53.7M |
| Debt / equity | 0.07 | 0.10 | 0.11 | 0.10 | 0.02 | — | — |
| Debt / assets | 0.05 | 0.07 | 0.08 | 0.07 | 0.02 | 0.05 | 0.16 |
| Current ratio | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 | 11.53 | 11.43 |
| Quick ratio | 5.50 | 3.81 | 4.74 | 5.67 | 11.43 | 11.32 | 10.64 |
| Interest coverage | -358.1 | -304.7 | — | — | -61.9 | -62.2 | -98.3 |
| Working capital | $665.1M | $526.8M | $345.0M | $469.5M | $488.1M | $243.3M | $69.7M |
| Invested capital | $465.5M | $548.9M | $122.5M | −$13.1M | $37.9M | −$452.8M | −$178.0M |
| Tangible asset value | $658.8M | $550.1M | $374.9M | $483.7M | $540.8M | −$208.8M | −$124.3M |
| Net current asset value | $469.6M | $300.5M | $247.9M | $354.3M | $467.3M | −$238.4M | −$149.3M |
| Graham net-net per share | $0.94 | $0.79 | $0.97 | $1.92 | $2.68 | −$1.45 | −$0.92 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | — | $0 | — | — |
| Capex / revenue | 8.7% | 23.3% | 27.2% | 94.1% | 398.0% | 197.3% | 228.5% |
| Capex / depreciation | 0.08 | 0.38 | 0.49 | 3.18 | 4.74 | 1.71 | 1.57 |
| Stock-based compensation / revenue | 148.9% | 138.8% | 121.9% | 70.3% | 148.4% | 125.8% | 80.9% |
| R&D / revenue | 569.4% | 534.4% | 549.8% | 392.4% | 1,352.7% | 1,855.2% | 2,677.3% |
| SG&A / revenue | 236.5% | 302.8% | 252.6% | 205.6% | 576.8% | 740.1% | 1,107.6% |
| Efficiency | |||||||
| Days sales outstanding | 180.4 | 162.1 | 24.3 | 54.5 | 168.7 | 16.4 | 32.2 |
| Days of inventory on hand | — | — | -7.8 | 10.7 | 132.2 | 29.8 | 42.1 |
| Days payables outstanding | 59.9 | 103.1 | 36.6 | 28.0 | 78.0 | 6.7 | 10.0 |
| Cash conversion cycle (days) | 120.4 | 59.0 | -20.0 | 37.2 | 222.9 | 39.5 | 64.3 |
| Receivables turnover | 2.02 | 2.25 | 15.01 | 6.70 | 2.16 | 22.23 | 11.33 |
| Payables turnover | 6.09 | 3.54 | 9.97 | 13.04 | 4.68 | 54.23 | 36.33 |
| Inventory turnover | — | — | — | 34.09 | 2.76 | 12.26 | 8.66 |
| Asset turnover | 0.05 | 0.06 | 0.06 | 0.06 | 0.02 | 0.02 | 0.02 |
| Average receivables | $36.9M | $26.1M | $2.9M | $5.9M | $4.6M | $153,500 | $151,000 |
| Average payables | $19.9M | $12.8M | $4.3M | $3.7M | $1.9M | $1.2M | $1.3M |
| Average inventory | — | — | −$907,000 | $1.4M | $3.3M | $5.2M | $5.3M |
| Intangibles / total assets | 32.0% | 33.5% | 13.5% | 0.3% | 0.4% | 0.8% | 0.0% |
Computed from RXRX's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RXRX valuation and financial ratios
Recursion Pharmaceuticals earned a return on equity of −59.5% and a return on invested capital of −100.9% in fiscal 2025. It ended the year with $78.0 million of debt and $743.3 million in cash and short-term investments, a net cash position of $665.3 million. The share count rose 169.9% from 165.8M to 447.4M over 6 years.
See the RXRX income statement, the RXRX chart for price history, or the RXRX stock overview for the latest quote and news.
RXRX key metrics FAQ
What is Recursion Pharmaceuticals's return on equity?
Recursion Pharmaceuticals's return on equity (ROE) was −59.5% in fiscal 2025: net income of -$644.8 million on average shareholders' equity of $1.1 billion.
What is Recursion Pharmaceuticals's ROIC?
Recursion Pharmaceuticals's return on invested capital was −100.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals had total debt of $78.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
What is Recursion Pharmaceuticals's free cash flow yield?
Recursion Pharmaceuticals generated -$378.3 million of free cash flow in fiscal 2025, a free cash flow yield of −20.7% on its market value at year-end ($1.8 billion).
What is Recursion Pharmaceuticals's current ratio?
Recursion Pharmaceuticals's current ratio was 5.50 at the end of fiscal 2025: current assets were 5.50 times current liabilities.